BBLG
Income statement / Annual
Last year (2024), Bone Biologics Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Bone Biologics Corporation's net income was -$4.11 M.
See Bone Biologics Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$50.00
|
$96.00
|
$96.00
|
$700.00
|
$4.45 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$50.00
|
-$96.00
|
-$96.00
|
-$700.00
|
-$4.45 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.13 M
|
$6.91 M
|
$1.58 M
|
$82.04 K
|
$340.67 K
|
$1.10 M
|
$104.49 K
|
-$1.19 M
|
$11.60 M
|
$3.67 M
|
| General & Administrative Expenses |
$2.09 M
|
$2.52 M
|
$2.09 M
|
$1.02 M
|
$484.34 K
|
$1.35 M
|
$2.69 M
|
$3.82 M
|
$6.25 M
|
$8.33 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.09 M
|
$2.52 M
|
$2.09 M
|
$1.02 M
|
$484.34 K
|
$1.35 M
|
$2.69 M
|
$3.82 M
|
$6.25 M
|
$8.33 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$44.00
|
$0.00
|
$0.00
|
$510.00
|
$567.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.22 M
|
$9.43 M
|
$3.67 M
|
$1.10 M
|
$825.01 K
|
$2.45 M
|
$2.79 M
|
$2.63 M
|
$17.85 M
|
$12.00 M
|
| Cost And Expenses |
$4.22 M
|
$9.43 M
|
$3.67 M
|
$1.10 M
|
$825.01 K
|
$2.45 M
|
$2.79 M
|
$2.63 M
|
$20.41 M
|
$12.00 M
|
| Interest Income |
$55.66 K
|
$1.87 K
|
$731.71
|
$805.11
|
$998.08
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$731.71 K
|
$805.11 K
|
$998.08 K
|
$975.77 K
|
$1.23 M
|
$4.42 M
|
$2.62 M
|
$1.87 M
|
| Depreciation & Amortization |
$0.00
|
$9.43 M
|
$3.67 M
|
$1.10 M
|
$50.00
|
$50.00
|
$96.00
|
$96.00
|
$700.00
|
$4.45 K
|
| EBITDA |
-$4.11 M |
$479.57 K |
-$4.40 M |
-$1.10 M |
-$825.00 K |
-$2.45 M |
-$2.79 M |
-$2.63 M |
-$20.41 M |
-$11.99 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$106.74 K
|
$479.57 K
|
$2.18 M
|
-$508.00 K
|
-$998.00 K
|
-$975.77 K
|
-$1.64 M
|
-$4.42 M
|
-$615.00 K
|
-$1.87 M
|
| Income Before Tax |
-$7.33 M
|
-$8.95 M
|
-$1.49 M
|
-$1.61 M
|
-$1.82 M
|
-$3.42 M
|
-$4.43 M
|
-$7.05 M
|
-$21.03 M
|
-$13.87 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$1.60 K
|
$1.60 K
|
$1.60 K
|
$1.73 K
|
$1.60 K
|
$2.24 K
|
$8.84 K
|
| Net Income |
-$4.11 M
|
-$8.95 M
|
-$1.49 M
|
-$1.61 M
|
-$1.83 M
|
-$3.42 M
|
-$4.43 M
|
-$7.05 M
|
-$25.88 M
|
-$13.88 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.83 |
-34.01 |
-31.15 |
-37.35 |
-35.68 |
-66.97 |
-3173.58 |
-6480 |
-24840 |
-17640 |
| EPS Diluted |
-4.83 |
-34.01 |
-31.2 |
-37.35 |
-35.68 |
-66.97 |
-3173.58 |
-6480 |
-24840 |
-17640 |
| Weighted Average Shares Out |
$1.52 M
|
$263.14 K
|
$47.60 K
|
$43.00 K
|
$51.00 K
|
$51.00 K
|
$1.40 K
|
$1.08 K
|
$1.05 K
|
$790.62
|
| Weighted Average Shares Out Diluted |
$1.52 M
|
$263.14 K
|
$47.66 K
|
$43.13 K
|
$51.14 K
|
$51.14 K
|
$1.40 K
|
$1.08 K
|
$1.05 K
|
$790.62
|
| Link |
|
|
|
|
|
|
|
|
|
|
